GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Interest Expense (Positive)

Summit Therapeutics (LSE:SUMM) Interest Expense (Positive)


View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


Summit Therapeutics (LSE:SUMM) Business Description

Traded in Other Exchanges
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.